1. Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity.
- Author
-
Jianping Huang, Jochems, Caroline, Anderson, Austin M., Talaie, Tara, Jales, Alessandra, Madan, Ravi A., Hodge, James W., Tsang, Kwong Y., Liewehr, David J., Steinberg, Seth M., Gulley, James L., and Schlom, Jeffrey
- Subjects
- *
T cells , *LIGANDS (Biochemistry) , *IMMUNOREGULATION , *TUMORS , *CELLULAR immunity , *CELL proliferation - Abstract
The interaction between CD27 and its ligand, CD70, has been implicated in regulating cellular immune responses to cancer. In this article, we report on the role of soluble CD27 (sCD27) in T cell activation and its elevation in the serum of cancer patients after immunotherapy. In vitro, sCD27 is preferentially derived from activated CD4+ T cells. Adding sCD27 to stimulated PBMCs increases T cell activation and proliferation, and is associated with the immunologic synapse-related proteins myosin IIA, high mobility group box 1, and the TCR VĪ²-chain. The pool of serum sCD27 is shown to be greater in healthy donors than in cancer patients. However, metastatic cancer patients treated with immunotherapy showed a significant increase in the serum sCD27-pool posttherapy (p < 0.0005); there was also an increased trend toward an association between enhanced sCD27-pool posttherapy and overall survival (p = 0.022). The identification of sCD27 as an immune modulator associated with enhanced human T cell activation in vitro and in vivo provides a rationale for developing new immunotherapeutic strategies aimed at enhancing sCD27 for treating cancer and potentially other diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF